Extended Data Table 1 ∣.
Intracranial benefit by histology of primary tumor
| Clinical benefit (RANO) |
||||
|---|---|---|---|---|
| No | Yes | |||
| N | % | N | % | |
| All | 33 | 57.9 | 24 | 42.1 |
| Initial Primary Tumor Diagnosis | ||||
| Breast | 22 | 62.9 | 13 | 37.1 |
| HR+ HER2+ | 5 | 55.6 | 4 | 44.4 |
| HR+ HER2− | 4 | 57.1 | 3 | 42.9 |
| HR+ HER2 Unknown | - | - | 1 | 100.0 |
| HR− HER2+ | 6 | 85.7 | 1 | 14.3 |
| Triple Negative | 7 | 63.6 | 4 | 36.4 |
| Extraosseous osteosarcoma | 1 | 100.0 | - | - |
| Melanoma | - | - | 2 | 100.0 |
| Esophageal | 1 | 100.0 | - | - |
| Neuroendocrine Carcinoma | 1 | 50.0 | 1 | 50.0 |
| Non-Small Cell Lung Cancer NOS | 4 | 57.1 | 3 | 42.9 |
| Ovarian | - | - | 1 | 100.0 |
| Pituitary carcinoma | - | - | 1 | 100.0 |
| Prostate | - | - | 1 | 100.0 |
| Renal Cell Carcinoma | 1 | 100.0 | - | - |
| Small Cell Lung Cancer | 2 | 100.0 | - | - |
| Adenocarcinoma of unknown primary | 1 | 100.0 | - | - |
| Advanced sino-nasal ACC | - | - | 1 | 100.0 |
| Alveolar soft part sarcoma | – | – | 1 | 100.0 |
A summary of intracranial benefit according to primary diagnosis is presented. Clinical benefit occurred in 37% (13/35) of patients with breast cancer and 43% (3/7) of patients with NSCLC. Both patients with melanoma BMs achieved intracranial benefit. For patients with breast cancer, summaries according to cancer subtype are provided. Using a Fisher’s exact test with a two-sided P value, there was no significant relationship between clinical benefit and either breast cancer subtype (P = 0.55) or HR status (P = 0.31). No adjustment was made for multiple comparison.